[{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Horizon Therapeutics \/ University of Michigan","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ University of Michigan"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"URAT1","graph1":"Rheumatology","graph2":"Approved","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fuji Yakuhin \/ Fortress Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Fuji Yakuhin \/ Fortress Biotech"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dotinurad","moa":"URAT1","graph1":"Rheumatology","graph2":"Approved","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fortress Biotech \/ Fuji Yakuhin","highestDevelopmentStatusID":"12","companyTruncated":"Fortress Biotech \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"COX","graph1":"Rheumatology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Rheumatology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Rheumatology","graph2":"Approved","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RxOMEG Therapeutics \/ Scilex Holding","highestDevelopmentStatusID":"12","companyTruncated":"RxOMEG Therapeutics \/ Scilex Holding"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Rheumatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","graph1":"Rheumatology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Urica Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fuji Yakuhin \/ Urica Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Fuji Yakuhin \/ Urica Therapeutics"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Febuxostat","moa":"Xanthine oxidase","graph1":"Rheumatology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Febuxostat","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Avion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Avion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Corticotropin","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Wellbeam Consumer Health","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Arnica Montana","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Wellbeam Consumer Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Wellbeam Consumer Health \/ Carlin Consumer Health","highestDevelopmentStatusID":"12","companyTruncated":"Wellbeam Consumer Health \/ Carlin Consumer Health"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Colchicine capsule (0.6 mg) is a generic version of Hikma's Mitigare has been approved by USFDA, it is indicated for prophylaxis of gout flares in adults.

                          Brand Name : Mitigare-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 30, 2021

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Granules India

                          02

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Colchicine capsules inhibits the beta tubulin polymerisation into microtubules, which is indicated for the prophylaxis of gout flares in adults patients.

                          Brand Name : Mitigare-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 11, 2020

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Granules India

                          03

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is indicated for prophylaxis of gout flares in adults and Familial Mediterranean fever (FMF) in adults and children 4 years or older

                          Brand Name : Colcrys-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 06, 2020

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Granules India

                          04

                          Details : With this approval, RINVOQ® (upadacitinib 15 mg, once daily) is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the European Union (EU).

                          Brand Name : Rinvoq

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 29, 2022

                          Lead Product(s) : Upadacitinib

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Abbvie Company Banner

                          05

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is indicated for prophylaxis of gout flares in adults and Familial Mediterranean fever (FMF) in adults and children 4 years or older

                          Brand Name : Colcrys-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 11, 2022

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Strides Pharma Science

                          06

                          Lead Product(s) : Febuxostat

                          Therapeutic Area : Rheumatology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Febuxostat Tablets, is a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets. Dr. Reddy’s Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.

                          Brand Name : Febuxostat-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 11, 2021

                          Lead Product(s) : Febuxostat

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Dr Reddy Company Banner

                          07

                          Lead Product(s) : Diclofenac Sodium

                          Therapeutic Area : Rheumatology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : The launch of Dr. Reddy’s Diclofenac Sodium Topical Gel, 1% (OTC), is an important addition to the Pain/ Analgesics portfolio of OTC products, and represents the continued commitment to the Private Label OTC space.

                          Brand Name : Diclofenac Sodium-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 09, 2020

                          Lead Product(s) : Diclofenac Sodium

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Dr Reddy Company Banner

                          08

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : The Colcrys® (colchicine) brand and generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health.

                          Brand Name : Colchicine-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 12, 2020

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Dr Reddy Company Banner

                          09

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.

                          Brand Name : Urece

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 08, 2024

                          Lead Product(s) : Dotinurad

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Gloperba (colchicine) liquid oral solution is a USFDA approved, tubulin inhibitor small molecule drug candidate which is indicated for prophylaxis of gout flares in adults.

                          Brand Name : Gloperba

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 29, 2024

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank